PARTNERING
Tyriaq works with:
- Regional and international manufacturing partners and suppliers, supporting production of key products and specialized formulations
- Bioequivalence centers recognized across the MENA region, ensuring that our development programs follow Egypt and GCC regulatory standards
- Clinical research and academic institutions that contribute to our enhanced medicines and fixed-dose combination programs
- Technology and digital health innovators that strengthen R&D capabilities and patient-support initiatives
Through these partnerships, Tyriaq aims to co-create solutions that address real therapeutic needs and align with regional regulatory and healthcare priorities.
Manufacturing & Supply
Tyriaq collaborates with established manufacturers across the Middle East to ensure high-quality, compliant, and scalable production of value-enhanced medicines and fixed-dose combinations.
These collaborations allow us to maintain:
- Consistent GMP-compliant production
- Regulatory alignment with SFDA, EDA, and relevant GCC requirements
- Scalable capacity for new launches across our core therapeutic areas
- Reliable supply-chain performance to meet regional demand
We welcome opportunities for:
- Toll manufacturing
- Technology transfer for select product lines
- Shared development and co-branding arrangements when strategically aligned
Tyriaq’s manufacturing and supply strategy is built on strong partnerships that ensure quality, compliance, and accessibility while supporting the region’s broader goal of expanding local pharmaceutical capabilities.
Research Partnerships
Research partnerships play a key role in Tyriaq’s stepwise approach to innovation. We collaborate with organizations that can strengthen our scientific rigor, support development of value-enhanced medicines, and help us build future therapeutic capabilities.
Tyriaq works with:
- Clinical experts and key opinion leaders across multiple therapeutic areas
- Bioequivalence centers recognized across the MENA region, ensuring development programs follow Egypt and GCC regulatory standards
- CROs and academic institutions that support clinical development, regulatory pathways, and technical assessments
- Technology and R&D laboratories contributing to formulation science and delivery technologies
- Digital health collaborators enabling insights, modeling, and patient-centric research